Online inquiry

IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6274MR)

This product GTTS-WQ6274MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets HA gene. The antibody can be applied in Influenza A infection research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_308669.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3654620
UniProt ID Q9Q0U6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6274MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8504MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ3437MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ12210MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ9028MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ11453MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ10277MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ2647MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 592
GTTS-WQ2744MR IVTScrip™ mRNA-Anti-IL23A, AMG-139(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG-139
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW